Last reviewed · How we verify
Klebsiella Nosocomial Pneumonia — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cipro | ciprofloxacin | Bayer AG | Fluoroquinolone antibiotic | DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A | 1987-10-22 | |
| Ofloxacine | Ofloxacine | Assistance Publique - Hôpitaux de Paris | Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1 | |||
| Ciprofloxacine | Ciprofloxacine | Poitiers University Hospital | DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Klebsiella Nosocomial Pneumonia
- Assistance Publique - Hôpitaux de Paris · 1 drug in Klebsiella Nosocomial Pneumonia
- Bayer AG · 1 drug in Klebsiella Nosocomial Pneumonia
- Poitiers University Hospital · 1 drug in Klebsiella Nosocomial Pneumonia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Klebsiella Nosocomial Pneumonia:
- Klebsiella Nosocomial Pneumonia treatment updates — RSS
- Klebsiella Nosocomial Pneumonia treatment updates — Atom
- Klebsiella Nosocomial Pneumonia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Klebsiella Nosocomial Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-nosocomial-pneumonia. Accessed 2026-06-10.
Related
- Klebsiella Nosocomial Pneumonia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing